18.01.2017
Medios AG DE000A1MMCC8
DGAP-News: Medios AG founds a new subsidiary: Medios Digital
DGAP-News: Medios AG / Key word(s): Investment
Medios AG founds a new subsidiary: Medios Digital
18.01.2017 / 11:59
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Corporate News
Medios AG founds a new subsidiary: Medios Digital
Berlin, January 18, 2017 - Medios AG hereby announces that it has founded a
wholly owned subsidiary, Medios Digital GmbH. With a registered office in
Berlin, Medios Digital GmbH has been endowed with a share capital of
EUR100,000. The purpose of the company is to render development,
consultancy and operational services in the field of information technology
and systems technology; in particular, to render software development
services, as well as software maintenance and software support services.
In the future, all software development activities performed by stocklisted
Medios AG and all of the group's other companies (Medios Pharma GmbH that
specializes in the wholesale distribution of specialty pharmaceutical drugs
as well as Medios Manufaktur GmbH, the special manufacturer for customized
pharmaceuticals for patients) will be bundled at Medios Digital GmbH.
Thanks to its unique, innovative commercial platform in the specialty
pharma field, the Medios Group sees itself as a competent link between
pharmaceutical companies, pharmacies and other pharmaceutical clients, such
as manufacturing companies. The full digitalization of the commercial
platform will be one of the main focuses of Medios Digital GmbH. In the
future, all partner pharmacies and clients will, among other things, have
the opportunity to access the latest offers online and also to plan and
place their orders online.
Medios AG
Matthias Gärtner, board member
About Medios AG
Medios AG, along with its subsidiaries Medios Pharma GmbH and Medios
Manufaktur GmbH, has positioned itself in the specialty pharma segment as
the go-to source for expertise and solutions. It brings together individual
market players in a network of cooperating partners. Our objective is to
ensure that patients have optimum access to pharmaceutical drugs and to
offer integrated solutions along the value-added chain to partners and
customers. Specialty pharmaceutical drugs are medications for patients with
rare and/or chronic illnesses (for example, certain cancers, or autoimmune
diseases and infectious diseases) that require lengthy and expensive
treatment.
Contact
Medios AG
Matthias Gärtner
Friedrichstraße 113a
10117 Berlin
Phone: +49 30 232 5668 0
Fax: +49 30 232 5668 66
E-Mail: [email protected]
www.medios.ag
Disclaimer
This notification contains forward-looking statements that are subject to
certain risks and uncertainties. Future results may significantly deviate
from currently expected results, specifically due to various risk factors
and uncertainties such as changes in business, economic, and competitive
circumstances, exchange rate fluctuations, uncertainties about legal
disputes or investigations, and the availability of financial resources.
Medios AG assumes no responsibility whatsoever for updating the forward-
looking statements contained in this notification.
---------------------------------------------------------------------------
18.01.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Medios AG
Friedrichstraße 113a
10117 Berlin
Germany
Phone: +49 30 232 566 - 800
Fax: 030 / 8321 8377
E-mail: [email protected]
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (General Standard), Hamburg;
Regulated Unofficial Market in Dusseldorf
End of News DGAP News Service
---------------------------------------------------------------------------
537367 18.01.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Medios AG ISIN: DE000A1MMCC8 können Sie bei EQS abrufen
Gesundheit , A1MMCC , ILM1 , XETR:ILM1